Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 464

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Coronavirus Disease 2019 (COVID‐19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Open access
Guo, Junyi, Huang, Zheng, Lin, Li, Lv, Jiagao·2020·Journal of the American Heart Association

Abstract

he prevalence of coronavirus disease 2019 (COVID-19) has posed a great threat to people's health worldwide, bringing a great challenges to the public healthcare systems.A recent study has confirmed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses severe acute respiratory syndrome coronavirus (SARS-CoV) receptor angiotensin-converting enzyme 2 (ACE2) for host cell entry. 1 ACE2 expression was previously found to correlate with susceptibility to SARS-CoV infection in vitro. 2 As with SARS-CoV, higher ACE2 expression might also lead to higher risk of SARS-CoV-2 infection. See Article by Sommerstein et al.According to available clinical data, ≈15% to 30% of the COVID-19 patients are with hypertension and ≈2.5% to 15% are with coronary heart disease.[3][4][5] Angiotensinconverting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are widely used in the treatment of these cardiovascular diseases.Interestingly, several studies have shown that ACEIs/ARBs exhibit ability to upregulate ACE2 expression in addition to their main pharmacological effect to inhibit angiotensin-converting enzyme 1 (ACE1) or block angiotensin II type 1 receptor.[6][7][8] Considering that ACE2 expression might correlate with the susceptibility to SARS-CoV-2, intake of ACEIs/ ARBs might predispose patients to the infection of SARS-CoV-2.Therefore, some cardiologists suggested that patients should discontinue ACEIs/ARBs to avoid the potential increased risk of SARS-CoV-2 infection.9 However, there is evidence demonstrating that the activation of the renin-angiotensin system (RAS) and the downregulation of ACE2 expression are involved in the pathological process of lung injury after SARS-CoV infection.10 Recently, it has been reported that serum level of angiotensin II is significantly elevated in COVID-19 patients and exhibits a linear positive correlation to viral load and lung injury.11 Activation of the RAS can cause widespread endothelial dysfunction and varying degrees of multiple organ (heart, kidney, and lung) injuries.Thus, intake of ACEIs/ARBs might probably relieve

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.120.016219

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 464

Metadata

Authors
Guo, J., Huang, Z., Lin, L., & Lv, J.
Venue
Journal of the American Heart Association
Published
2020-04-09
Volume
9
Issue
7
Pages
e016219-e016219
ISSN
2047-9980 (ISSN-L)
OpenAlex
W3013921190
Cited by
464
References
18
FWCI
13.13
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Coronavirus Disease 2019 (COVID‐19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. https://app.cochat.ai/papers/10.1161/jaha.120.016219
The paper
Guo, J., Huang, Z., Lin, L., & Lv, J. (2020). Coronavirus Disease 2019 (COVID‐19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of the American Heart Association. https://doi.org/10.1161/jaha.120.016219

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.